Cartalax + BPC-157 + TB-500 10mg/5mg/5mg blend

Cartalax 10 mg + BPC-157 5 mg + TB-500 5 mg is a high-purity multi-peptide research preparation supplied exclusively for scientific investigation and controlled laboratory experimentation. For research use only — not for human or veterinary use.  

Product Overview

Cartalax 10 mg + BPC-157 5 mg + TB-500 5 mg is a multi-peptide research preparation combining three independently characterised peptide components within a single lyophilized research vial. The formulation contains 10 mg Cartalax, 5 mg BPC-157 and 5 mg Thymosin Beta 4 (TB-500), providing a total nominal peptide content of 20 mg. Each component represents a distinct area of experimental peptide research. Cartalax is investigated within controlled laboratory models involving short-chain peptide chemistry and molecular interactions. BPC-157 is studied within experimental peptide and cellular signalling systems, while Thymosin Beta 4 is examined within controlled peptide biology and molecular research. Independent third-party laboratory analysis of this production batch measured assay contents of 10.61 mg Cartalax, 5.31 mg BPC-157 and 5.27 mg Thymosin Beta 4 (TB-500). Chromatographic analysis confirmed greater than 99.8 percent purity for all three independently analysed peptide components. Identity was independently evaluated through FTIR spectrum analysis and retention time confirmation for Cartalax, BPC-157 and Thymosin Beta 4 (TB-500). Microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count, while bacterial endotoxin analysis returned a result below 0.001 EU/mg. Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. With all three peptide components independently characterised, this multi-peptide preparation provides researchers with extensive batch-specific analytical documentation suitable for advanced peptide investigations and controlled in vitro laboratory studies.  

Peptide Overview

This 20 mg research preparation combines three distinct peptide components: Cartalax, BPC-157 and Thymosin Beta 4 (TB-500). Cartalax is a short-chain peptide research compound investigated within experimental peptide chemistry, molecular interactions and biochemical research models. BPC-157 is a synthetic peptide research compound utilised in controlled investigations involving peptide-mediated molecular interactions and cellular signalling systems. Thymosin Beta 4 is a peptide research compound investigated within experimental cellular biology, peptide interactions and molecular signalling research. Combining these three compounds within a single research preparation provides investigators with a multi-component material for controlled comparative and combined peptide investigations. For this production batch, Liquilabs independently evaluated assay content, purity, FTIR spectrum identity and retention time identity for all three peptide components.  

Historical Background and Scientific Context

Advances in peptide synthesis and analytical chemistry have enabled researchers to develop increasingly sophisticated multi-component peptide preparations for controlled scientific investigation. Modern analytical technologies make it possible to independently characterise individual compounds within combined peptide preparations rather than evaluating only the formulation as a whole. Chromatographic techniques can independently determine assay content, purity and retention time characteristics for individual peptide components, while spectrum-based analysis provides complementary identity information. Microbiological analysis, bacterial endotoxin testing and elemental impurity screening further contribute to comprehensive batch-specific analytical characterisation. Cartalax 10 mg + BPC-157 5 mg + TB-500 5 mg represents a multi-peptide research preparation in which all three components have been independently evaluated within the same production batch.  

Mechanistic Focus in Research

Within controlled laboratory environments, the individual components may be investigated in relation to peptide chemistry, molecular signalling and cellular communication systems. Research investigations frequently explore:

• Multi-peptide interaction research
• Short-chain peptide investigations
• Peptide-mediated signalling pathways
• Intracellular molecular communication
• Cellular regulatory mechanisms
• Biochemical pathway analysis
• Molecular peptide interactions
• Comparative peptide investigations
• Controlled in vitro multi-peptide studies

These experimental models allow researchers to investigate multiple peptide-related molecular systems while maintaining carefully controlled laboratory conditions.  

Analytical Verification (COA)

Each batch of Cartalax 10 mg + BPC-157 5 mg + TB-500 5 mg supplied by Grail Formula undergoes comprehensive independent third-party laboratory verification to characterise the individual peptide components and important laboratory quality parameters. Analytical testing for this batch was performed by Liquilabs s.r.o. Czechia using chromatographic, spectrometric and microbiological analytical techniques. Batch: GF-CATBBP-B241

• Cartalax Content: 10 mg
• Cartalax Assay Content: 10.61 mg
• Cartalax Purity: greater than 99.8 %
• Cartalax Identification by FTIR Spectrum: 997
• Cartalax Identification by Retention Time: 0.991
• BPC-157 Content: 5 mg
• BPC-157 Assay Content: 5.31 mg
• BPC-157 Purity: greater than 99.8 %
• BPC-157 Identification by FTIR Spectrum: 994
• BPC-157 Identification by Retention Time: 0.982
• Thymosin Beta 4 (TB-500) Content: 5 mg
• Thymosin Beta 4 (TB-500) Assay Content: 5.27 mg
• Thymosin Beta 4 (TB-500) Purity: greater than 99.8 %
• Thymosin Beta 4 (TB-500) Identification by FTIR Spectrum: 973
• Thymosin Beta 4 (TB-500) Identification by Retention Time: 0.987
• Bacterial Endotoxins: below 0.001 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening measured assay contents of 10.61 mg for Cartalax, 5.31 mg for BPC-157 and 5.27 mg for Thymosin Beta 4 (TB-500). Purity analysis confirmed greater than 99.8 percent purity for each of the three independently analysed peptide components. FTIR spectrum analysis returned identity results of 997 for Cartalax, 994 for BPC-157 and 973 for Thymosin Beta 4 (TB-500). Retention time analysis returned 0.991 for Cartalax, 0.982 for BPC-157 and 0.987 for Thymosin Beta 4 (TB-500). Bacterial endotoxin testing returned a result below 0.001 EU/mg. Microbiological testing reported 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count. Independent elemental impurity analysis reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. These analytical procedures provide extensive independent batch-specific characterisation of all three peptide components together with microbiological, endotoxin and elemental impurity testing.  

Research Applications

Within controlled laboratory environments, Cartalax 10 mg + BPC-157 5 mg + TB-500 5 mg may be utilised in experimental models designed to investigate multi-peptide biology, molecular signalling and biochemical interactions. Examples of research applications include:

• Multi-peptide interaction investigations
• Cartalax peptide research
• BPC-157 peptide investigations
• Thymosin Beta 4 peptide research
• Peptide-mediated signalling studies
• Intracellular signalling investigations
• Molecular pathway analysis
• Comparative peptide investigations
• Controlled in vitro multi-peptide studies

These applications are intended exclusively for scientific and laboratory investigation.  

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification and transparent batch-specific laboratory documentation. For this multi-peptide production batch, independent laboratory testing included:

• Individual assay determination for all three peptide components
• Individual purity assessment for all three peptide components
• FTIR spectrum identity analysis
• Retention time identity verification
• Bacterial endotoxin analysis
• Total aerobic microbial count
• Total yeast and mold count
• Comprehensive elemental impurity screening
• Complete batch-specific traceability

Independent analysis of each peptide component provides researchers with detailed analytical information relating directly to the tested production batch rather than relying solely on the nominal formulation. This approach supports analytical transparency, batch traceability and consistency across Grail Formula research compounds.  

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently analysed research compounds supported by detailed Certificates of Analysis and transparent batch-specific laboratory documentation. For Cartalax 10 mg + BPC-157 5 mg + TB-500 5 mg batch GF-CATBBP-B241, independent analysis was performed by Liquilabs s.r.o. Czechia and the Certificate of Analysis was published on 20 September 2026. All three peptide components were independently evaluated for assay content, purity, FTIR spectrum identity and retention time identity. The analytical programme additionally included bacterial endotoxin testing, microbiological analysis and comprehensive elemental impurity screening. This multi-method analytical approach provides researchers with extensive independent information regarding the individual components within the tested multi-peptide research preparation.  

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Contains 10 mg Cartalax, 5 mg BPC-157 and 5 mg Thymosin Beta 4 (TB-500)
• Greater than 99.8 % purity confirmed for all three peptide components
• Cartalax assay content verified at 10.61 mg
• BPC-157 assay content verified at 5.31 mg
• Thymosin Beta 4 (TB-500) assay content verified at 5.27 mg
• Identification confirmed by FTIR spectrum and retention time analysis
• Bacterial endotoxin level below 0.001 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mold count: 0 CFU/g
• All reported elemental impurities below 0.001 ppm
• Multi-peptide research preparation with complete COA traceability
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.